Boston Scientific (BSX) Stock Looks Cheap On Earnings And Fair Value
Boston Scientific stock is down about 49.8% over the past year, yet the current checks suggest the shares may now sit at a discount to what the company’s cash flows imply. Both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples are pointing to Boston Scientific trading below what these models consider a fair value.
- Over the last year the share price declined 49.8%, which puts recent weakness and sentiment at odds with models that indicate the stock may now be pricing in a lot of bad news.
- The growing pulsed field ablation market and Boston Scientific’s FARAPULSE system can support expectations for future cash flows, while any setback in adoption or competitive pressure may limit how much of that growth ultimately reaches shareholders.
- On Simply Wall St’s broader checks, Boston Scientific screens as undervalued in 5 of 6 areas. This suggests the valuation picture leans cheap overall compared with its fundamentals and peers, based on the company’s valuation score of 5.
The issue now is whether Boston Scientific’s current share price already reflects the risks in its recent share price decline or whether the discount indicated by the intrinsic value models and multiples still leaves meaningful upside on the table.
Find out why Boston Scientific's -49.8% return over the last year is lagging behind its peers.
Does Boston Scientific Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Boston Scientific is worth based on the cash it can generate for shareholders. The latest twelve month free cash flow sits at about $3.6b, and the model assumes these cash flows continue growing from this base rather than shrinking.
On that basis, the 2 Stage Free Cash Flow to Equity model points to an intrinsic value of about $84.93 per share. Compared with the current share price, the DCF implies the stock trades at roughly a 39.0% discount, which suggests it may be undervalued. The pulsed field ablation report highlighting the FARAPULSE system helps explain why the model still supports solid future cash generation, even after the sharp share price decline.
Overall, Boston Scientific stock currently appears undervalued relative to what its projected cash flows suggest.
Our Discounted Cash Flow (DCF) analysis suggests Boston Scientific is undervalued by 39.0%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.
Is Boston Scientific a Bargain on Earnings?
P/E suits Boston Scientific because earnings are a key focus for investors in established medical equipment companies. The stock currently trades on a P/E of about 20.4x, which is below both the Medical Equipment industry average of roughly 26.2x and the peer group average of about 41.7x. On raw comparisons, the market is assigning Boston Scientific a lower earnings multiple than many similar companies.
A more tailored benchmark for Boston Scientific is the modelled fair P/E ratio of about 29.1x. This fair ratio reflects what investors might typically pay for the company’s profile, including its margins, growth outlook, market position and risk factors. The gap between the current 20.4x and the 29.1x fair level suggests the market price does not fully reflect the earnings power implied by those fundamentals.
On the P/E multiple alone, Boston Scientific stock appears undervalued relative to both peers and the modelled fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The Boston Scientific Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Boston Scientific valuation puzzle leaves off and explain what growth, margin and earnings paths would need to hold for the stock to be worth materially more or less than today's price. Instead of relying on a single multiple or model output, each Narrative sets out the assumptions behind its fair value so you can compare them with Boston Scientific's actual results as they are reported on the Community page.
The Boston Scientific community is split between a bullish view on acquisition driven upside and a cautious read on product and growth headwinds.
Bull case: 48% undervalued
"The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons..."
Read the full Bull Case to see why Boston Scientific could be undervalued
Bear case: 18% overvalued
"However, management’s lower 2026 organic revenue guidance of 6.5% to 8% highlights that any benefit to top line growth could be uneven..."
Read the full Bear Case to see why Boston Scientific could be overvalued
Do you think there's more to the story for Boston Scientific? Head over to our Community to see what others are saying!
The Bottom Line
For Boston Scientific, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple view currently point to an undervalued stock rather than one that looks fully priced. The broader checks also lean supportive, which makes the current discount harder to ignore if you think the business can convert its product pipeline into sustained cash generation.
The key question from here is whether Boston Scientific can keep pulsed field ablation and the wider portfolio growing in a way that supports those cash flow assumptions. That balance between growth and execution risk remains the core divide between potential value opportunity and a valuation that is simply reflecting real uncertainty.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com